BamSEC and AlphaSense Join Forces
Learn More

Sutro Biopharma Inc.

NASDAQ: STRO    
Share price (12/20/24): $1.88    
Market cap (12/20/24): $155 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 13 pages Sutro Biopharma, Inc. Sutro Biopharma, Inc. Amended 2018 Employee Stock Purchase Plan 1
12/34/56
EX-10.1
from 10-Q 94 pages Recitals
12/34/56
EX-10.43
from 10-K 44 pages Manufacturing Rights Agreement
12/34/56
EX-10.34
from 10-K 37 pages Sutro Biopharma, Inc. Amended and Restated 2021 Equity Inducement Plan
12/34/56
EX-10.30
from 10-K 8 pages January 18, 2023 1. Compensation
12/34/56
EX-10.24
from 10-K 11 pages Sutro Biopharma, Inc. Severance and Change in Control Plan Section 1 Purpose
12/34/56
EX-10.14
from 10-K 8 pages August 28, 2023 1. Compensation
12/34/56
EX-10.1
from 10-Q 10 pages Third Amendment to Amended and Restated Sutrovax Agreement
12/34/56
EX-10.1
from 10-Q 76 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sutro Biopharma, Inc. if Publicly Disclosed. Purchase and Sale Agreement Dated as of June 21, 2023 Between Sutro Biopharma, Inc. and Bxls V – Vault L.P
12/34/56
EX-10
from 10-K 12 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.2
from 10-Q 92 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sutro Biopharma, Inc. if Publicly Disclosed. License and Collaboration Agreement by and Between Sutro Biopharma, Inc. and Astellas Pharma Inc. June 27, 2022 I
12/34/56
EX-10.1
from 10-Q 7 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sutro Biopharma, Inc. if Publicly Disclosed. Amendment to License Agreement
12/34/56
EX-10.31
from 10-K 12 pages Material contract
12/34/56
EX-10.30
from 10-K 10 pages May 23, 2021 1. Compensation 2. Stock Equity
12/34/56
EX-10.29
from 10-K 64 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sutro Biopharma, Inc. if Publicly Disclosed. License Agreement by and Between Sutro Biopharma, Inc. and Tasly Biopharmaceuticals Co., Ltd. December 20, 2021 License Agreement
12/34/56
EX-10.28
from 10-K 80 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sutro Biopharma, Inc. if Publicly Disclosed. Option and License Agreement
12/34/56
EX-10.11
from 10-K 11 pages Biologics by Design. Imagine. December 11, 2012
12/34/56
EX-10.2
from 10-Q 5 pages Second Amendment to the Exclusive Patent License and Research Collaboration Agreement
12/34/56
EX-10.2
from 10-Q 2 pages 2. Renewal Option
12/34/56
EX-10.1
from 10-Q 11 pages Severance and Change in Control Plan Section 1 Purpose
12/34/56